CTLA4 and lung carcinoma: Immunotherapy, especially against immune checkpoints, such as PD1 or cytotoxic T lymphocytes associated protein 4 (CTLA4), has been approved for the treatment of multiple solid malignancies, including lung cancer.48, 49, 50